--- ## Safety, Side Effects & Monitoring ### Common Side Effects | Peptide | Common Effects | Management | |---------|---------------|------------| | CJC-1295 | Mild fatigue, water retention | Reduces over time | | Ipamorelin | Headache (rare), injection site reaction | Very well tolerated | | GHRP-6 | Intense hunger, water retention | Discuss with your provider | | IGF-1 LR3 | Hypoglycemia risk, joint pain | Requires monitoring | ### Safety Protocols 1
GLOW co-formulates it with GHK-Cu (50 mg) and TB-500 (10 mg)
We observed that in the NAC treated cohort, a significant increase of dopamine function in the primary dopamine areas of the basal ganglia could be observed coupled with improvements in standard clinical scores ( The current study of patients with MS utilized our previously developed protocol using a combination of oral and intravenous NAC administered for 2 months to patients with MS
Although this practice is common across biomedical research, it has unintended consequence of systematically removing female-specific biological variability from the evidence base
UDP glucuronsyltransferase (UGT) 1A6 pharmacogenetics, II
